Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-18 02:01 UTC

BIOMED PULSE

Monday, August 18, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo is now officially the largest Ebola outbreak ever recorded in that country, with sustained transmission, expanding geography, and mounting casualties as of August 14, 2026. The overall mood is urgent on the outbreak front and cautiously productive on the longevity science side.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (DRC) - RECORD-BREAKING OUTBREAK

  • WHO's August 14 Disease Outbreak News (DON-615) declares the Bundibugyo virus disease (BVD) outbreak in DRC is now in a phase of intense transmission and is the largest Ebola outbreak ever reported in the country. [1]
  • As of July 15, 2026, the cumulative toll stood at 2,124 confirmed cases and 828 deaths in the DRC, with ongoing cross-border transmission to Uganda already documented since May 2026. [2]
  • The outbreak began in Mongbwalu Health Zone, Ituri Province, first detected around May 5, 2026, and has since expanded to multiple health zones and provinces over roughly three months. [3]
  • CDC mobilized an international Ebola response beginning May 17, 2026, and enhanced airport screening was activated at Washington-Dulles and Atlanta Hartsfield airports in late May 2026. [4] [5]
  • WHO confirmed the outbreak via the Institut national de recherche biomedicale (INRB) in DRC on May 14, 2026, with the Bundibugyo strain distinguishing this event from the more common Ebola Zaire strain. [6]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP

  • WHO's fifth DON update (DON-611, July 2, 2026) confirmed the Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship, first reported May 2, 2026, remains under active multi-country surveillance. [7]
  • The outbreak originated aboard a vessel carrying 147 passengers and crew; initial reporting identified 2 laboratory-confirmed ANDV cases and 5 suspected cases as of May 4, 2026, with additional cases confirmed in subsequent updates. [8] [9] [10]
  • CDC provided hantavirus response transcripts through June 24, 2026, indicating continued monitoring of exposed passengers and crew across multiple countries.

CYCLOSPORA - TACO BELL LINKED OUTBREAK

  • CDC confirmed shredded iceberg lettuce served at Taco Bell locations is the source of Cyclospora infections across five states, with 1,644 people sickened as of July 17, 2026.
  • The outbreak expanded to four additional states as of July 24, 2026, underscoring the scale of this foodborne parasitic event.

SALMONELLA - JALAPENOS

  • CDC issued a food safety alert on August 5, 2026, warning of a multistate Salmonella outbreak linked to jalapeños.

WEST NILE VIRUS - EARLY SEASON SURGE

  • CDC reported an early and record West Nile virus season in the United States as of July 1, 2026, urging mosquito-bite prevention over the America 250th Independence Day holiday weekend.

MEASLES - BANGLADESH

  • WHO's DON-598 (April 23, 2026) reported Bangladesh notified WHO of 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts nationwide.

NIPAH VIRUS - INDIA

  • WHO's DON-609 (June 25, 2026) confirmed one laboratory-confirmed Nipah virus (NiV) infection in an adult male in Kozhikode district, Kerala State, India, with symptom onset May 30, 2026.

AVIAN INFLUENZA A(H9N2) - ITALY

  • WHO's DON-597 (April 10, 2026) reported a human A(H9N2) case in an adult male returning to Italy from Senegal, confirmed via next-generation sequencing.

KINDERGARTEN VACCINATION RATES

  • CDC data released August 17, 2026 show U.S. kindergarten vaccination rates remain high overall, with only a slight 0.1% decline in coverage from the prior year.

🧬 LONGEVITY & AGING

PUNICALAGIN AND BONE AGING

  • A study published in Regenerative Therapy (Wang et al., July 25, 2026) found that punicalagin, a polyphenol compound, alleviates senile osteoporosis by inhibiting the senescence of bone mesenchymal stem cells via the NRF2/HO-1 antioxidant pathway in an aged model.
  • This adds to a growing body of evidence linking cellular senescence - the state where aging cells stop dividing but remain metabolically active and inflammatory - to bone loss in older adults.

EGFR LOSS AND IMPAIRED FRACTURE HEALING IN AGED MICE

  • Research published in Bioactive Materials (Hu et al., August 4, 2026) found that loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells is directly associated with impaired fracture healing in aged mice.
  • The finding points to EGFR signaling as a potential therapeutic target for improving bone repair outcomes in elderly patients, who currently face much higher complication rates post-fracture.

SENESCENCE IN OSTEOARTHRITIS - DUAL-MODAL TARGETING

  • A study in Bioactive Materials (An et al., July 31, 2026) demonstrated that combining antioxidant and epigenetic therapies creates a synergistic effect that breaks the self-perpetuating senescence cycle driving osteoarthritis joint degeneration.
  • The approach targets both the oxidative stress and the epigenetic reprogramming that lock joint cells into a pro-inflammatory, aging state - a dual attack strategy gaining traction in geroscience.

TELOMERE REPAIR AND CANCER CELL AGING

  • Research in Nucleus (Salmina et al., July 23, 2026) examined how telomeric DNA repair and misrepair interact with PML nuclear bodies and lamin B1 in doxorubicin-treated cancer cells, illuminating how cancer cells manipulate aging machinery to survive chemotherapy.
  • Telomere integrity is a core hallmark of biological aging, and understanding its misrepair mechanisms has direct implications for both cancer treatment and healthy longevity research.

METFORMIN PLUS LIFESTYLE FOR OLDER ADULTS WITH OBESITY - DEMFOS TRIAL

  • The DEMFOS randomized controlled trial, published in Lancet Healthy Longevity (Nava et al., 2026), found that adding metformin to a lifestyle intervention improved physical function in older adults with obesity compared to lifestyle alone.
  • An accompanying editorial by Witham and McDonald cautioned that while results are promising, expectations for metformin as a broad frailty remedy should remain measured until larger trials confirm the findings.

STATIN DEPRESCRIBING IN ADULTS AGED 75 AND OLDER - SAGA/SITE TRIAL

  • The SAGA/SITE multicentre, open-label, non-inferiority randomized trial published in Lancet Healthy Longevity (Bonnet et al., 2026) examined whether stopping statins for primary cardiovascular prevention in adults aged 75 and older is safe.
  • An accompanying commentary (Arya Nezhad et al.) argued the results should shift clinical conversations toward individual-based decisions about statin continuation in this age group rather than a one-size-fits-all policy.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN OLDER ADULTS

  • A study in Blood Pressure (Laati et al., August 7, 2026) using two Finnish generational cohorts born 20 years apart found that positive life orientation is associated with lower blood pressure in older adults, suggesting psychological factors are measurable biological levers for cardiovascular aging.

CANINE EPIGENETIC AGING AND DIET

  • A pilot study in Veterinary Record Open (Chen et al., August 5, 2026) found that feeding dogs a minimally processed, human-grade diet measurably altered their epigenetic aging clock compared to standard processed kibble, offering a potential animal model for studying diet-longevity interactions.

UDP-GlcNAc NANOSHEETS AND LYSOSOMAL AMPK FOR LIVER DISEASE

  • Research in Bioactive Materials (Zhu et al., July 12, 2026) showed that targeting the ROAM1 protein with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK, resolving metabolic dysfunction-associated steatotic liver disease (MASLD) in a model system - a novel entry point for metabolic aging therapies.

💊 NEW CURES & APPROVALS

WINREVAIR (SOTATERCEPT-CSRK) - MERCK SHARP DOHME

  • Merck Sharp Dohme received a supplemental FDA approval (SUPPL AP) for Winrevair (sotatercept-csrk, BLA761363), an activin signaling inhibitor approved for pulmonary arterial hypertension (PAH), expanding its label.
  • Sotatercept works by rebalancing the TGF-beta superfamily signaling pathway that drives aberrant vascular remodeling in PAH, a mechanism distinct from all prior PAH drugs.

OPDIVO (NIVOLUMAB) - BRISTOL MYERS SQUIBB

  • Bristol Myers Squibb received a supplemental FDA approval (SUPPL AP) for Opdivo (nivolumab, BLA125554), the PD-1 immune checkpoint inhibitor, reflecting a new or expanded oncology indication.

HEPZATO (MELPHALAN HYDROCHLORIDE) - DELCATH SYSTEMS INC

  • Delcath Systems Inc received a supplemental FDA approval (SUPPL AP) for Hepzato (melphalan hydrochloride, NDA201848), a hepatic delivery chemotherapy system used in liver-directed cancer treatment.

XIGDUO XR (DAPAGLIFLOZIN/METFORMIN) - ASTRAZENECA AB

  • AstraZeneca AB received a supplemental FDA approval for Xigduo XR (dapagliflozin plus metformin hydrochloride, NDA205649), a combined SGLT2 inhibitor and biguanide oral diabetes therapy.

SYNJARDY XR (EMPAGLIFLOZIN/METFORMIN) - BOEHRINGER INGELHEIM

  • Boehringer Ingelheim received a supplemental FDA approval for Synjardy XR (empagliflozin plus metformin hydrochloride, NDA208658), another SGLT2 inhibitor/metformin combination for type 2 diabetes.

FOSFOMYCIN TROMETHAMINE - NOVITIUM PHARMA

  • Novitium Pharma received an original FDA approval (ORIG AP) for fosfomycin tromethamine (ANDA210426), a cell-wall synthesis inhibitor antibiotic used for uncomplicated urinary tract infections.

NOTE: All drug approval records carry invalid dates in source data; specific approval dates cannot be confirmed from the supplied records. Items reflect FDA supplemental and original application actions as listed in Drugs@FDA.

🧪 CLINICAL TRIALS

AMYLOID PET IMAGING IN THE BALTIMORE LONGITUDINAL STUDY OF AGING

  • A new trial (NCT07099053, registered August 17, 2026) will use amyloid PET imaging scans to track amyloid protein accumulation in participants enrolled in the long-running Baltimore Longitudinal Study of Aging, aiming to link amyloid burden to cognitive decline trajectories over time.

FRAILTY AND MUSCLE STRENGTH PREDICTION BEFORE MAJOR SURGERY

  • Trial NCT06988176 (registered August 17, 2026) is an observational study testing whether simple frailty and muscle strength assessments can predict postoperative complications in adults aged 65 and older undergoing major abdominal surgery.

PF-08634404 IN TRANSFORMED SMALL CELL LUNG CANCER - SYMBIOTIC-LUNG-14

  • Trial NCT07476287 (registered August 17, 2026) will study PF-08634404, a new investigational agent, alone and in combination with chemotherapy in adults with transformed small cell lung cancer, evaluating efficacy and safety.

INHALED AZACYTIDINE PLUS DURVALUMAB FOR EARLY NSCLC - AZA-AEGEAN

  • Trial NCT06694454 (registered August 17, 2026) tests neoadjuvant inhaled azacytidine combined with platinum-based chemotherapy and durvalumab (MEDI4736) as a combined epigenetic-immunotherapy regimen for operable early-stage non-small cell lung cancer, addressing the high recurrence rate after surgical resection.

BARICITINIB IN JOB SYNDROME WITH LUPUS-LIKE DISEASE OR ATOPIC DERMATITIS

  • Trial NCT07262983 (registered August 17, 2026) evaluates the JAK1/JAK2 inhibitor baricitinib for safety and tolerability in patients with autosomal dominant hyper-IgE syndrome (Job syndrome) presenting with lupus-like disease or atopic dermatitis.

NEOANTIGEN TCR T CELL THERAPY FOR HEMATOLOGIC MALIGNANCIES WITH TP53 OR RAS MUTATIONS

  • Trial NCT06904066 (registered August 17, 2026) tests autologous T cells transduced with retroviral vectors expressing T-cell receptors targeting patient-specific neoantigens in blood cancers driven by TP53 or RAS mutations.

TRIADENO VACCINE PLUS IL-15 SUPERAGONIST N-803 IN PROSTATE CANCER ACTIVE SURVEILLANCE

  • Trial NCT07574541 (registered August 17, 2026) tests a multitargeted recombinant Ad5 PSA/MUC-1/brachyury vaccine (TriAdeno) combined with IL-15 superagonist N-803 in men with localized low-grade prostate cancer on active surveillance, where 35% historically require treatment within 5 years.

📢 PUBLIC HEALTH

MULTI-COUNTRY INFANT FORMULA RECALL - CEREULIDE TOXIN IN ARA OIL

  • WHO DON-596 (March 13, 2026) reported multi-country recalls of infant formula and other products after cereulide toxin was detected in batches linked to contaminated arachidonic acid (ARA) oil used as an ingredient across multiple internationally distributed brands.

SALMONELLA OUTBREAK LINKED TO JALAPEÑOS

  • CDC warned August 5, 2026 of a new multistate Salmonella outbreak linked to jalapeños; consumers should check CDC's food safety alert page and discard any implicated products.

EXTENSIVELY DRUG-RESISTANT SALMONELLA IN MORINGA POWDER

  • As of February 13, 2026, CDC reported an extensively drug-resistant Salmonella outbreak tied to moringa powder capsules, with three hospitalizations and no deaths at that time; the moringa alert was later updated on May 27, 2026 showing a growing number of illnesses linked to moringa leaf products broadly.

CDC BIOSURVEILLANCE MILESTONE

  • CDC announced January 30, 2026 that its Traveler-Based Genomic Surveillance program surpassed 1 million voluntary air travel participants, enhancing the agency's ability to detect novel pathogen variants entering the United States.

U.S. WHO WITHDRAWAL COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, with CDC noting a shift toward bilateral health efforts; WHO stated the withdrawal makes both the U.S. and the world less safe.

TIMOR-LESTE CERTIFIED MALARIA-FREE

  • WHO certified Timor-Leste malaria-free on July 23-24, 2025, recognizing a nationwide elimination effort begun after independence in 2002 - a milestone in tropical disease eradication.

This briefing is informational only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  5. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  8. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
  9. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
  10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260818-02-v59 · 2026-08-18 02:01 UTC · pulse.uzylab.com

Read next